zole or other drugs are used as the initial treatment [2, 3, [5] [6] [7] [8] [9] [10] [11] [12] .
At the end of 2002, we noted an increase in the incidence of nosocomial CDAD and the case-fatality rate at our institution (Centre Hospitalier Universitaire de Sherbrooke [CHUS] , Sherbrooke, Quebec, Canada), as had occurred in other hospitals of the province of Quebec [13] . A retrospective (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) study of the epidemiology of CDAD in our region confirmed that there had been an increase in the severity of this infection and showed that the use of vancomycin as primary treatment was associated with a lower frequency of progression to complicated colitis and/or of death within 30 days after diagnosis, compared with metronidazole [14] . Herein, we examine whether the frequency of relapses changed during this 13-year period, to which we have added data from the first 6 months of 2004.
METHODS
The methods have been described in detail elsewhere [14] . In brief, cases of CDAD diagnosed during the period of January 1991 through June 2004 at the CHUS were reviewed. CHUS is a teaching hospital that provides care to the ∼300,000 inhabitants of the Estrie region, and its clinical microbiology laboratory is the sole laboratory to perform the C. difficile toxin assay in the region. The same C. difficile toxin B cytotoxin assay was used throughout that period. Patients with a positive toxin assay result were identified through the hospital computerized medical records. Additionally, for inpatients, cases of pseudomembranous colitis, antibiotic-associated colitis, or C. difficile colitis were identified through the hospital discharge database. We defined patients with CDAD as patients who met at least 1 of the following criteria: a positive C. difficile cytotoxin assay result, endoscopic evidence of pseudomembranous colitis, or histopathologic evidence of pseudomembranous colitis on an endoscopic biopsy specimen or a specimen obtained during colectomy or autopsy. CDAD was considered to have been hospital acquired if the patient had been hospitalized when the inciting antibiotics were administered. Two episodes of CDAD in the same patient were considered to be distinct events if they occurred 12 months apart; an episode that occurred within 2 months after a prior one was considered to be a recurrence of the initial episode. Medical records were reviewed to extract demographic, clinical, and laboratory data [14] .
A recurrence of CDAD can correspond to either a relapse with the same strain or a reinfection with a different strain. Because it is impossible in clinical practice to differentiate between these 2 mechanisms, we will use the term "recurrence" to designate both. A patient was considered to have had a recurrence if, within 2 months of the initial diagnosis, (1) there was recurrence of diarrhea, and (2) an additional specimen was positive for C. difficile toxin or the attending physician ordered a second course of treatment for C. difficile. In the current report, we restricted our analyses to patients who lived in the Estrie region, for whom toxin assays ordered by attending physicians suspecting a recurrence would normally have been sent to CHUS, and to patients who were treated at CHUS and for whom the initial treatment was known. The primary analyses focused on patients who were treated with only 1 drug. Patients treated with metronidazole received the drug at a dosage of 250 mg 4 times per day or 500 mg 3 times per day for 10-14 days. Most patients treated with oral vancomycin received 125 mg 4 times per day for the same duration, although some patients (especially in 2003-2004) received 250-500 mg 4 times per day. As a proxy for reexposure to C. difficile spores, we measured the number of days that each patient was hospitalized within the 60 days that followed the initial diagnosis of CDAD.
Proportions were compared with the Yates-corrected x 2 test. Kaplan-Meier analyses were used to measure the probability of recurrences after the initial treatment. For patients who did not experience relapse, data were censored when the patient died or 60 days after the diagnosis of the initial episode. Log rank tests were used to compare risk factors for recurrences in univariate analyses. Cox proportional hazards modeling was used for multivariate analyses. Models were built up sequentially, starting with the variable most strongly associated with the outcome and continuing until no other variable reached significance. When the final model was reached, each variable was dropped in turn to assess its effect on the model. Different models were compared using the likelihood ratio test. In the final models, we kept variables that were significant at the level. The proportional hazards assumption was verified P р .05 by comparing the Kaplan-Meier curve to the Cox predicted curve for a given variable and by assessing the parallel nature of curves in log-log plots.
RESULTS
A total of 2042 patients fulfilled the case definition. There were substantial changes over time in their age distribution, site of acquisition, proportion with a high leukocyte count, and other characteristics ( Figure 1 , top, shows the Kaplan-Meier plot of the probability of recurrence according to the year of diagnosis. Figure 2 shows the probability of recurrence according to age group. During 1991-2002, the 60-day probabilities of recurrence were 20.0%, 13.8%, and 28.9% for patients aged 0-17, 18-64, and у65 years, respectively. During 2003-2004, the 60-day probabilities of recurrence were 25.0%, 27.1%, and 58.4%, respectively, for the same age groups.
When compared with patients who did not spend any days in the hospital within 2 months of diagnosis of CDAD, patients Yes 11 (7) 10 (5) 18 (9) 24 (13) 26 (11) 38 (17) 72 (12) 1, bottom) . In univariate analysis, a peak P p .12 creatinine level of у200 mmol/L was associated with a higher risk of recurrence, but this was no longer significant after ad- justment for age, which was itself strongly associated with recurrences (hazard ratio, 1.03 for each year of age; 95% CI, 1.01-1.06). Neither diagnosis in 2003-2004, hospital acquisition, duration of hospitalization after the diagnosis of CDAD, nor other characteristics were significantly associated with recurrence after receipt of vancomycin therapy.
A total of 139 patients were treated initially with metronidazole and later had therapy switched to oral vancomycin because the attending physician estimated that the former was ineffective; 53 (38.1%) of these patients had at least 1 recurrence (46 [87%] of 53 cases were proven by a repeated toxin assay)
The 60-day probability of recurrence was 31.2% for patients who received diagnoses in 1991-2002 and 39.4% for those who received diagnoses in 2003-2004 ( ). Neither age, sex, P p .28 year of diagnosis, duration of hospitalization after the diagnosis, nor other clinical and biological factors predicted recurrences.
DISCUSSION
A large range of risk of recurrence after metronidazole (5%-23%) and vancomycin (9%-24%) therapy for CDAD has been reported, mostly in small studies [2, 3, 7, 11, 12] . In a larger study from the 1980s, 24% of 189 patients given vancomycin experienced a recurrence [5] , whereas 6% of 632 patients treated with metronidazole and 9% of 122 patients given vancomycin did so in another study [6] . Recent reviews state that the frequencies of recurrence after vancomycin therapy and metronidazole therapy are similar (20%-25%) [9, [15] [16] [17] [18] . These crude measures, which did not take into consideration the completeness of follow-up or survival rates, somewhat underestimated the true risk of recurrence, because patients who died rapidly-whether of CDAD or of some other disease-had little opportunity to experience relapse.
At our institution, the frequency of recurrence of CDAD after metronidazole therapy more than doubled in 2003-2004, even after adjustment for the substantial aging of our inpatients [19] . There are 4 potential explanations for this finding. First, the considerable impact of the 2003-2004 epidemic [14] might have influenced the propensity of physicians to order an additional toxin assay and/or a second treatment when diarrhea recurred, potentially causing an ascertainment bias. Second, C. difficile might have developed some degree of resistance to metronidazole. Third, the highly virulent strain associated with the current epidemic in Quebec might have specific virulence factors favoring relapses. Fourth, in 2003 Fourth, in -2004 , patients who remained hospitalized after the diagnosis of CDAD might have been more heavily reexposed to C. difficile spores in the hospital environment and reinfected than were earlier cohorts.
Fecal metronidazole levels in patients who are given the drug orally are higher in watery stools at the beginning of treatment (mean, 9.3 mg/g of wet weight) than in semiformed stools obtained a few days later (3.3 mg/g); its hydroxymetabolite, which has activity against C. difficile, is detectable at roughly the same levels [20] . Thus, fecal metronidazole levels decrease as colonic inflammation subsides, in contrast with the administration of oral vancomycin, which results in very high fecal concentrations (1000-3000 mg/mL), maintained for the duration of therapy [21] . Under these conditions, even a modest increase in the MIC might suffice for a substantial proportion of patients ending up with fecal metronidazole levels that are under this threshold after a few days of treatment. This might also explain why the patients in our study who had initially been treated with metronidazole had, after adjustment for confounders, a risk of progressing to a complicated form of C. difficile colitis identical to that of patients who had received no treatment [14] .
In an attempt to distinguish epidemiologically between re-lapses and reinfections, we measured the number of days that patients remained hospitalized within 2 months after the initial diagnosis of CDAD. Given that C. difficile spores are presumably more abundant in the hospital environment than in patients' homes, the number of days spent in hospital should be a good proxy for reexposure. Our data suggest that reinfections played a marginal role in the higher risk of recurrences after metronidazole therapy in [2003] [2004] and that most such episodes were genuine relapses. Compared with patients who spent no time in the hospital after diagnosis, those who were hospitalized for 1-15 and 16-30 days were not more likely to experience a recurrence, after adjustment for the confounding factors of age, year of diagnosis, and hospital acquisition of infection. Recurrences were much less likely among patients who spent 130 days in the hospital. The latter intriguing finding might reflect the building-up of immunity among patients who remained exposed and/or a selection process: if some patients are more prone to experiencing relapse than are others, perhaps through a weaker immune response to C. difficile toxins, this might tend to occur within a short period after the end of initial treatment, so that those who have not had relapse within 1 month after diagnosis-even if reexposed-might be patients who are intrinsically less susceptible. This effect was so strong that it seems unlikely to represent some unmeasured confounding. Given the high fecal levels of vancomycin, one would not expect clinically relevant resistance to that drug to occur, unless there is perhaps suboptimal drug penetration into spores. The trend towards a higher frequency of recurrences after receipt of vancomycin therapy in 2003-2004 might be viewed as support for the hypothesis that reinfections occurred more frequently, but chance or an ascertainment bias may also explain this finding in that small number of patients. This will be monitored in the future as additional patients are treated with vancomycin.
Age of у65 years was associated with a higher risk of recurrences of CDAD after metronidazole and vancomycin therapy. Cohort studies showed that lower levels of antibodies against C. difficile toxin A and age of 165 years were associated with recurrences; baseline and day 12 anti-toxin A IgG concentrations did not differ on the basis of age, but power was limited in these studies [22, 23] . Older patients with many comorbidities may be more likely to receive additional antibiotics to treat concomitant infections.
Our data underline the need for large, randomized, controlled trials to evaluate novel therapeutic agents against C. difficile. Since the early 1980s, no attempt has been made to experiment with therapies that might result in fewer cases of recurrence than the 25% usually reported; such frequent failures are not accepted for other common infections. We are now using vancomycin as the initial treatment for patients with a leukocyte count of 120,000 cells/mm 3 and/or a creatinine level of 1200 mmol/L-a subgroup of patients with a high shortterm mortality rate [14] . Such an approach should not be generalized to other populations of patients with CDAD, to limit the selective pressure for the emergence of vancomycin-resistant pathogens. Longer duration of metronidazole treatment would probably not have an impact on relapses, given that the secretion of metronidazole decreases as colonic inflammation subsides. Administration of metronidazole at the highest dosage (750 mg t.i.d.) might be considered. Current expert opinions recommend that metronidazole should be used as the standard treatment for a first relapse of CDAD [8, 9, 17, 18, 21] . Given the high relapse rate seen when metronidazole is used as the initial treatment, many clinicians in Quebec are now using vancomycin to treat the first relapse after completion of metronidazole therapy. Data are collected to determine whether this might reduce the risk of a second relapse.
The efficacy of the probiotic Saccharomyces boulardii in reducing the risk of a first relapse was not clearly demonstrated [24, 25] . Fusidic acid and bacitracin were associated with a higher risk of relapse than was metronidazole [5, 7] . Tinidazole has similar in vitro activity to metronidazole and has more favorable pharmacokinetics and is better tolerated [26] [27] [28] [29] [30] . Ramoplanin, nitazoxanide, and daptomycin also deserve further evaluation [31] [32] [33] .
Our data suggest that elderly patients should be treated more aggressively in the hope of reducing the morbidity, mortality, and costs associated with relapses. Furthermore, the poor effectiveness of metronidazole in 2003-2004, especially among older patients, might have had an impact on transmission dynamics, because patients with severe diarrhea for a longer duration (during initial episodes and relapses) had ample opportunity to disseminate spores in the hospital environment. Better treatments might be an important part of the quest for a better means of infection control.
The main limitations of our study are related to its observational nature. Physicians in 2003-2004 may have been more prone to diagnose a relapse of CDAD, given the magnitude of the CDAD epidemic. Most relapses were documented with a repeated toxin assay; however, C. difficile toxins can be present in stool samples obtained after treatment from asymptomatic patients [15] , and recurrence of diarrhea due to some other etiology (e.g., tube feeding or receipt of laxatives) may then be misdiagnosed as a relapse. Our results can not be directly generalized to regions outside of Quebec, because the higher postmetronidazole therapy relapse rate in 2003-2004 might be related to decreased susceptibility of a specific clone. However, the dominant strain of C. difficile in Quebec seems to be identical to one that was recently identified in the United States [34] .
In conclusion, we have documented, in the context of a largescale epidemic of C. difficile colitis in 2003-2004 associated with had a high case-fatality rate, an increase in the proportion of patients who did not respond to metronidazole (defined as a switch to vancomycin therapy) and a doubling of the proportion of patients who experienced relapse after treatment with metronidazole. These results emphasize the need for better surveillance of this common nosocomial infection and for monitoring the frequency of treatment failures and relapse rates in other geographic settings.
